HomeCompareCLOD vs PFE

CLOD vs PFE: Dividend Comparison 2026

CLOD yields 1.86% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $27.2K in total portfolio value· pulled ahead in Year 9
10 years
CLOD
CLOD
● Live price
1.86%
Share price
$25.70
Annual div
$0.48
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.4K
Annual income
$209.55
Full CLOD calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — CLOD vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLODPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLOD + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLOD pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLOD
Annual income on $10K today (after 15% tax)
$157.94/yr
After 10yr DRIP, annual income (after tax)
$178.12/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $22,141.79/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLOD + PFE for your $10,000?

CLOD: 50%PFE: 50%
100% PFE50/50100% CLOD
Portfolio after 10yr
$36.0K
Annual income
$13,234.14/yr
Blended yield
36.79%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

CLOD
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLOD buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLODPFE
Forward yield1.86%6.13%
Annual dividend / share$0.48$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$22.4K$49.6K
Annual income after 10y$209.55$26,258.71
Total dividends collected$2.0K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CLOD vs PFE ($10,000, DRIP)

YearCLOD PortfolioCLOD Income/yrPFE PortfolioPFE Income/yrGap
1$10,886$185.81$9,153$693.39+$1.7KCLOD
2$11,837$189.04$8,593$849.25+$3.2KCLOD
3$12,858$192.11$8,336$1,066.78+$4.5KCLOD
4$13,953$195.02$8,437$1,384.80+$5.5KCLOD
5$15,127$197.79$9,013$1,875.40+$6.1KCLOD
6$16,386$200.41$10,306$2,680.72+$6.1KCLOD
7$17,736$202.89$12,820$4,101.38+$4.9KCLOD
8$19,183$205.23$17,673$6,826.70+$1.5KCLOD
9← crossover$20,733$207.45$27,543$12,591.86$6.8KPFE
10$22,394$209.55$49,560$26,258.71$27.2KPFE

CLOD vs PFE: Complete Analysis 2026

CLODStock

CLOD seeks to emulate the performance of the Solactive Cloud Computing Index, representing companies in cloud computing across developed markets. The index starts from a universe of small-, mid-, and large-cap companies that may be classified within defined sub-industries of the cloud computing industry. Security selection is based on the free float market capitalization of all eligible securities with firms ranking at the top of each sub-industry chosen. Twenty companies from internet infrastructure software and data support software, 10 each from digital security software, data infrastructure software, and data architecture software industries, and 3 from e-commerce infrastructure software are considered where the top 50 securities by market-cap are selected for the index. Constituents are also weighted according to their free float market capitalization with a 4.5% cap placed on individual securities. This is to ensure diversification and to limit overconcentration. CLOD is rebalanced quarterly.

Full CLOD Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this CLOD vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLOD vs SCHDCLOD vs JEPICLOD vs OCLOD vs KOCLOD vs MAINCLOD vs JNJCLOD vs MRKCLOD vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.